Treatment of AML and MDS in Older Patients: A Case-Based Approach

NMDP breakfast symposium presented Friday December 7, preceding the 2012 ASH Annual Meeting 

Access Slides

This content will be available as an online CME activity beginning spring 2013. Check back for details.

• All four presentations (PDF) 
• Applying Novel Diagnostics and Therapeutics for AML in the Older Patient (PDF), Gail Roboz, M.D. 
• Transplantation for AML in the Older Patient: how and when should age matter? (PDF), Frederick Appelbaum, M.D. 
• Drug Therapy for MDS: Targets and Biomarkers (PDF), David Steensma, M.D. 
• MDS and AlloHCT: Weighing risks and benefits, and the need to learn more (PDF), Stephen Forman, M.D. 

Program description

Using a didactic and interactive case study approach, attendees will learn practical applications of classification and research data to compare treatment choices for older AML and MDS patients.  For AML, how has diagnostic testing changed the timing of therapeutic choices and how should age factor into the decision?  For aging MDS patients, how can the data be applied to mitigate risk and optimize the benefit between new drugs, transplantation, and the combination treatment approaches?  How will new research studies affect the options for Medicare-eligible patients?

Speakers

Gail Roboz, M.D
Associate Professor of Medicine, Weill Cornell Medical College
Associate Attending Physician, NewYork-Presbyterian Hospital

Frederick Appelbaum, M.D.
Executive Director, Seattle Cancer Care Alliance
Clinical Research Division, Director, Fred Hutchinson Cancer Research Center
Professor, Medical Oncology Division, University of Washington School of Medicine

David Steensma, M.D.
Associate Professor, Department of Medicine, Harvard Medical School
Attending Physician, Hematologic Oncology, Dana-Farber Cancer Institute
Attending Physician, Medicine, Brigham And Women's Hospital

Stephen Forman, M.D.
Chair, Hematology & Hematopoietic Cell Transplantation
Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation
Co-leader, Hematologic Malignancies Program, Comprehensive Cancer Center
Clinical Director, Cancer Immunotherapeutics & Tumor Immunology, City of Hope

Willis Navarro, M.D.
Medical Director, National Marrow Donor Program
Associate Clinical Professor of Medicine, University of California San Francisco

Questions? 

If you have any questions regarding this activity, call Renee Ryan at (800) 526-7809 ext. 8430, or e-mail rryan@nmdp.org.